Oncternal Therapeutics (ONCT) Competitors $0.53 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ONCT vs. APM, VRAX, CMND, SNGX, ONVO, ABVC, ALZN, FRTX, MAAQ, and CANFShould you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Aptorum Group (APM), Virax Biolabs Group (VRAX), Clearmind Medicine (CMND), Soligenix (SNGX), Organovo (ONVO), ABVC BioPharma (ABVC), Alzamend Neuro (ALZN), Fresh Tracks Therapeutics (FRTX), Mana Capital Acquisition (MAAQ), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. Oncternal Therapeutics vs. Aptorum Group Virax Biolabs Group Clearmind Medicine Soligenix Organovo ABVC BioPharma Alzamend Neuro Fresh Tracks Therapeutics Mana Capital Acquisition Can-Fite BioPharma Aptorum Group (NASDAQ:APM) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Do analysts prefer APM or ONCT? Oncternal Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 1,798.97%. Given Oncternal Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oncternal Therapeutics is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community believe in APM or ONCT? Aptorum Group received 9 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 68.33% of users gave Aptorum Group an outperform vote while only 24.24% of users gave Oncternal Therapeutics an outperform vote. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Oncternal TherapeuticsOutperform Votes3224.24% Underperform Votes10075.76% Which has stronger valuation and earnings, APM or ONCT? Aptorum Group has higher earnings, but lower revenue than Oncternal Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K13.19-$2.83MN/AN/AOncternal Therapeutics$790K1.97-$39.48M-$11.69-0.05 Does the media favor APM or ONCT? In the previous week, Aptorum Group's average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score. Company Overall Sentiment Aptorum Group Neutral Oncternal Therapeutics Neutral Do insiders and institutionals hold more shares of APM or ONCT? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, APM or ONCT? Aptorum Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Is APM or ONCT more profitable? Aptorum Group has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Aptorum Group's return on equity of 0.00% beat Oncternal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Oncternal Therapeutics -1,599.95%-177.58%-131.30% SummaryAptorum Group beats Oncternal Therapeutics on 8 of the 14 factors compared between the two stocks. Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCT vs. The Competition Export to ExcelMetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-0.056.1126.7719.18Price / Sales1.97268.25435.4570.78Price / CashN/A65.6738.0134.83Price / Book0.056.707.644.62Net Income-$39.48M$138.98M$3.19B$246.06M7 Day PerformanceN/A-2.63%-2.12%-2.63%1 Month PerformanceN/A-2.33%-0.45%-2.15%1 Year Performance-94.28%-5.33%16.26%12.88% Oncternal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCTOncternal Therapeutics1.5303 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530APMAptorum Group0.4972 of 5 stars$1.19-0.8%N/A-38.1%$6.16M$430,000.000.0030Gap UpVRAXVirax Biolabs Group0.8384 of 5 stars$1.90+1.3%N/A+93.9%$6.15M$160,000.000.005CMNDClearmind MedicineN/A$1.41+0.7%N/A-27.9%$6.02MN/A-0.75N/AGap UpSNGXSoligenix1.1949 of 5 stars$2.39-2.8%N/A-79.1%$6.00M$840,000.00-0.3220News CoverageONVOOrganovo1.1127 of 5 stars$0.39+2.1%N/A-63.1%$5.93M$110,000.00-0.3620Earnings ReportABVCABVC BioPharma1.1199 of 5 stars$0.46+8.9%N/A-41.2%$5.93M$150,000.00-0.5330News CoveragePositive NewsGap DownHigh Trading VolumeALZNAlzamend Neuro2.6121 of 5 stars$1.09+0.9%$32.00+2,835.8%-88.9%$5.92MN/A0.004Gap UpFRTXFresh Tracks TherapeuticsN/A$0.93-0.3%N/A-1.1%$5.55M$8.01M-0.6620MAAQMana Capital AcquisitionN/A$0.67-1.2%N/A-72.6%$5.44MN/A0.001High Trading VolumeCANFCan-Fite BioPharma1.9168 of 5 stars$1.53+1.0%$14.00+818.0%-11.7%$5.40M$740,000.00-0.858Analyst Forecast Related Companies and Tools Related Companies APM Alternatives VRAX Alternatives CMND Alternatives SNGX Alternatives ONVO Alternatives ABVC Alternatives ALZN Alternatives FRTX Alternatives MAAQ Alternatives CANF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredThis quote from Elon says it all… (AI Breakthrough)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
